Oncology Venture acquires rights to shelved Novartis drug

Oncology Venture spin-out company utilizes its option to acquire the rights for a phase 3 cancer drug from Swiss Novartis.

Danish Oncology Venture utilizes a previously agreed option to take over rights to develop and commercialize the cancer drug dovitinib from Novartis. Photo: /ritzau/Sofie Mathiassen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles